Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis.

Pallavi K, Chandra A, Kumar K, Martand K, Sahu SS, Mohan L, Verma A

Maedica1 Dec 2025

PMID41537067PMCIDPMC12767911DOI10.26574/maedica.2025.20.4.824PepBankPUB-41537067

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanSystematic reviewEfficacy outcome
In a meta-analysis of retatrutide trials in people with diabetes and/or obesity with chronic kidney disease, retatrutide treatment was linked with a mean HbA1c reduction of 1.04%.
In plain wordsIn a pooled analysis of trials, retatrutide treatment was linked to a lower HbA1c in people with diabetes, obesity or kidney disease.
Peptide
Retatrutide
Outcome
DecreaseHbA1c change
Study
n: not reported in source
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
HbA1c change
−1.04%
pooled mean
Source sentences
Summary
A significant mean reduction in HbA1c of -1.04% (95% CI -1.42 to -0.67)
2 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive literature search identified relevant randomized controlled trials for inclusion.
Summary · context
Eight studies were included in the present research work.
Report a problemFND-4153706701
02HumanSystematic reviewEfficacy outcome
In a meta-analysis of retatrutide trials, retatrutide treatment was linked with weight loss reaching up to 24.2%.
In plain wordsIn a pooled analysis of trials, retatrutide treatment was linked to weight loss of up to 24.2%.
Peptide
Retatrutide
Outcome
DecreaseWeight loss
Study
n: not reported in source
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Weight change
−24.2%
up to
Source sentences
Summary
a noticeable loss in weight, reaching up to -24.2%, were both linked with retatrutide treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive literature search identified relevant randomized controlled trials for inclusion.
Summary · context
Eight studies were included in the present research work.
Report a problemFND-4153706702
03HumanSystematic reviewEfficacy outcome
Secondary analyses of retatrutide trials pointed toward a reduction in albuminuria.
In plain wordsSecondary analyses of retatrutide trials pointed to lower albuminuria, a possible kidney benefit.
Peptide
Retatrutide
Outcome
DecreaseAlbuminuria
Study
n: not reported in source
Analysis
Secondary
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
Furthermore, secondary analyses pointed toward possible renoprotective effects, evidenced by a reduction in albuminuria.
2 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive literature search identified relevant randomized controlled trials for inclusion.
Summary · context
Eight studies were included in the present research work.
Report a problemFND-4153706705
04HumanSystematic reviewEfficacy outcome
In the subgroup analysis, lower retatrutide doses (8 mg or less) gave an HbA1c reduction of 1.39%.
In plain wordsIn a subgroup analysis, lower retatrutide doses (8 mg or less) lowered HbA1c by 1.39%, more than higher doses.
Peptide
Retatrutide
Outcome
DecreaseHbA1c change, lower doses
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
<=8 mgAs given in this study (human).
Measurements
HbA1c change
−1.39%
doses <=8 mg
Source sentences
Summary
lower doses (≤8 mg) demonstrating a greater HbA1c reduction (-1.39%)
2 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive literature search identified relevant randomized controlled trials for inclusion.
Summary · context
Eight studies were included in the present research work.
Report a problemFND-4153706703
05HumanSystematic reviewEfficacy outcome
In the subgroup analysis, higher retatrutide doses (12 mg or more) gave an HbA1c reduction of 0.65%, smaller than with lower doses.
In plain wordsIn a subgroup analysis, higher retatrutide doses (12 mg or more) lowered HbA1c by 0.65%, less than lower doses.
Peptide
Retatrutide
Outcome
DecreaseHbA1c change, higher doses
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
>=12 mgAs given in this study (human).
Measurements
HbA1c change
−0.65%
doses >=12 mg
Source sentences
Summary
higher doses (≥12 mg, -0.65%).
2 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive literature search identified relevant randomized controlled trials for inclusion.
Summary · context
Eight studies were included in the present research work.
Report a problemFND-4153706704
06HumanSystematic reviewSafety outcome
In the meta-analysis, the safety profile of retatrutide was mainly characterized by gastrointestinal adverse events.
In plain wordsIn the pooled analysis, retatrutide's side effects were mainly stomach and gut problems.
Peptide
Retatrutide
Outcome
Direction not reportedGastrointestinal adverse events
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
The safety profile is primarily characterized by gastrointestinal adverse events, which is anticipated for this drug class.
2 context sentences(design, population, supporting numbers)
Summary · context
A comprehensive literature search identified relevant randomized controlled trials for inclusion.
Summary · context
Eight studies were included in the present research work.
Report a problemFND-4153706706

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 10:21 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.